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Abstract
Background: Glycoprotein 210 (GP210) is a transmembrane component of the nuclear pore
complex of metazoans, with a short carboxyterminus protruding towards the cytoplasm. Its
function is unknown, but it is considered to be a major structural component of metazoan nuclear
pores. Yet, our previous findings showed pronounced differences in expression levels in embryonic
mouse tissues and cell lines. In order to identify factors regulating GP210, the genomic organization
of human GP210 was analyzed in silico.
Results: The human gene was mapped to chromosome 3 and consists of 40 exons spread over
102 kb. The deduced 1887 amino acid showed a high degree of alignment homology to previously
reported orthologues. Experimentally we defined two transcription initiation sites, 18 and 29 bp
upstream of the ATG start codon. The promoter region is characterized by a CpG island and
several consensus binding motifs for gene regulatory transcription factors, including clustered sites
associated with Sp1 and the Wilms' tumor suppressor gene zinc finger protein (WT1). In addition,
distal to the translation start we found a (GT)n repetitive sequence, an element known for its ability
to bind WT1. Homologies for these motifs could be identified in the corresponding mouse genomic
region. However, experimental tetracycline dependent induction of WT1 in SAOS osteosarcoma
cells did not influence GP210 transcription.
Conclusion: Although mouse GP210 was identified as an early response gene during induced
metanephric kidney development, and WT1 binding sites were identified in the promoter region
of the human GP210 gene, experimental modulation of WT1 expression did not influence
expression of GP210. Therefore, WT1 is probably not regulating GP210 expression. Instead, we
suggest that the identified Sp binding sites are involved.
Introduction
Nuclear pore complexes (NPCs) provide the only known
gateway for transport of RNAs to the cytoplasm and bidi-
rectional transport of proteins between the nucleus and
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the cytoplasm. The NPC in vertebrates has an estimated
mass of approximately 125 Mda. Structural studies sug-
gest an octagonal rotational symmetry framework, from
which 50–100-nm long fibrils extend into the nucleo-
plasm and cytoplasm. A comprehensive inventory of all
NPC constituents has been made for yeast [1] and meta-
zoans [2]. A polypeptide profile from purified rat liver
NPCs revealed ~50 putative nucleoporins [3].
In the list of metazoan nucleoporins, there are only two
integral membrane proteins, gp210 [4-6] and POM121
[7,8]. Both have been localized to the NPC structure, each
with a distinct membrane topology and amino acid
motifs. Primarily due to their location, both proteins are
presumed to anchor NPCs by the nuclear envelope and to
assemble nucleoporins postmitotically. No binding part-
ners have so far been identified for either of these pro-
teins. The 121-kDa pore membrane protein POM121
[7,8] is located in the pore membrane domain of the NPC
with a short (29 residues) N-terminal tail protruding into
the lumen of the nuclear envelope, with the C-terminus
facing the cytoplasm [8]. POM121 contains a C-terminal
tandem sequence repeat of a core XFXFG motif inter-
rupted by hydrophilic spacers. These motifs typical for
nucleoporins and have been shown to interact with com-
ponents of the soluble transport machinery [3,9].
In contrast to POM121, gp210 has an inverted topology
with its main bulk residing in the lumen of the NE and
only a short 58 residue C-terminal portion facing the NPC
[5,6]. The amino acid-sequence of gp210 lacks pentapep-
tide repeats indicating no direct interaction with the
mobile receptors directing nucleocytoplasmic transport
[5,10]. A 23-amino-acid hydrophobic peptide residing in
the luminal part of gp210 has been predicted to be
involved in formation of new pores acting as a nuclear
membrane fusion agent [5,11]. It has also been experi-
mentally shown that the C-terminus of gp210 is involved
in nuclear pore dilation [11], even though this is not a
conserved sequence in different species [12]. Remarkably,
it has also been shown that gp210 is essential for viability
of human HeLa cells and C. Elegans [13]. A fraction of the
cellular pool of gp210 can form dimers that may consti-
tute a lumenal submembranous protein skeleton [14].
The primary sequence of gp210 is known for rat [5] and
mouse [10]. Interestingly, whereas several nucleoporins
found in vertebrates have homologues in the completed
yeast genome, no such similarities have so far been
detected for POM121 or gp210. Possibly, this could be
related to the fact that the yeast nuclear membrane does
not break down during cell division, and assembly regula-
tors are not needed. In a comprehensive analysis of a
highly enriched NPC fraction, presumably containing all
yeast NPC proteins [1], only three transmembrane nucle-
oporins were detected, but these have no resemblance
with gp210 or POM121. Thus, if the role of POM121 or
gp210 in metazoans is to anchor the NPC, different pro-
teins or mechanisms should be involved in the anchorage
of yeast NPCs. Mouse gp210 was initially identified as an
early response gene to induction of metanephric kidney
development and data from other embryonic tissues con-
firmed the differential distribution of its mRNA [10] and
protein [15]. This suggested a novel cell-type specific reg-
ulation of gp210. It was thus of interest to characterize the
promoter region of the human GP210 gene.
In the current study we present the genomic structure of
the human integral membrane glycoprotein 210 gene
(GP210), the open reading frame sequence and a pro-
moter region analysis. This was done in silico by taking
advantage of the available human genomic sequence.
Transcription start sites were determined experimentally
by RNA ligase mediated rapid amplification of cDNA
ends. Computer-assisted searches of the promoter
sequence indicated putative consensus binding sites for
transcription factors involved in tissue specific gene regu-
lation. We also identified of shared putative cis-acting ele-
ments in the human promoter and its mouse counterpart.
Several putative Wilms tumor suppressor binding 1 sites
were found. Nevertheless, experimental overexpression of
WT1 in SAOS osteosarcoma cells did not influence GP210
mRNA expression.
Results
Organization of the human GP210 gene
We initially assumed that mouse gpP210 was a member of
a yet undiscovered large family of tissue-specific nuclear
pore membrane proteins, and initially named it POM210
[10] to emphasize the similar subcellular distribution
with POM121 [7]. Since current data suggest a surpris-
ingly low amount of pore membrane proteins both in ver-
tebrates and yeast, renaming is unnecessary. A BLAST
homology search was performed using the mouse gp210
cDNA sequence (POM210, accession AF113751) against
the working draft sequences of the human genome. This
identified a completed contig-component (clone RP11-
220D14, accession AC090942.1) localized to chromo-
some 3, in a region defined by three genomic markers
(stSG4499, Cda14e10 and WI-9637). These markers were
cytogenetically positioned to 3p25.1. By comparing to the
mouse cDNA sequence and taking advantage of the exon/
intron prediction program provided by the Genscan web
server, 40 exons covering 102551 bp were defined (see
Table 1, additional file 1). The exons ranged between 63
(exon 24) and 251 (exon 36) bp. All exon-intron junc-
tions conformed to the consensus splice donor (GT) and
acceptor (AG) sites, except for the splice donor sites of
intron 7 (AT) and10 (GC). The introns sizes were between
74 (intron 38) and 20198 bp (intron 1). Introns wereJournal of Negative Results in BioMedicine 2004, 3:7 http://www.jnrbm.com/content/3/1/7
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classified relative to codon interruption, as follows: phase
0 (no codon interruption), phase 1 (interruption between
first and second base) and phase 2 (after second base).
Exons were interrupted by introns of all phases. Most
introns were of phase 0 (55%). A number of efforts where
made to identify alternatively spliced products using PCR
with primer pairs directed to high probability putative
splice variant exons. However, no such variants could be
found. Manually, we could identify one single polyade-
nylation signal (AATAAA) 1423 nucleotides downstream
of the translation stop codon (Fig. 1). The exons formed
an ORF of 5664 bp including the stop codon.
Primary structure of GP210
The deduced amino acid sequence of human GP210 con-
tains 1887 residues, predicting a molecular mass of 205
198 Da and a pI of 6,41 of the non-processed protein.
Alignment to the corresponding mouse and rat sequences
displayed a high degree of homology (91,8% similarity
and 88,9% identity compared to the primary structure of
the rat protein). One insertion, an alanine at position
1858, makes the GP210 one residue longer compared to
rat and mouse GP210. A signal peptide cleavage consen-
sus site could be defined between residues 25 and 26
using the SignalP algorithm (Fig. 1). This signal sequence
shows no resemblance to previously reported GP210
sequences. Hydrophobicity values along the deduced
amino acid chain identified several putative membrane
spanning regions. One of these (residues 1809 to 1828)
corresponded to a domain mapped in the rat orthologe
[5], leaving 59 residues facing the nuclear pore. Motifs
found scanning the sequence through the ExPASy-Prosite
database included 12 potential N-glycosylation sites (out-
lined in Fig. 1), and numerous putative consensus sites for
various kinase related phosphorylations. Two cAMP- and
cGMP dependent protein kinase sites (residues 1089,
1874), two tyrosine kinase sites (residues 227, 922), 30
protein kinase C phosphorylation sites and 26 casein
kinase II phosphorylation sites were found. The sites asso-
ciated to PKC and CK2 phosphorylation were evenly dis-
tributed throughout the sequence. Blast homology
searches revealed a vast number of EST clones containing
GP210 sequence and an 871 amino acid partial sequence
of a hypothetical human protein KIAA09906 (accession
Xp051621) identical to the C-terminal end of the full
length translated GP210 open reading frame.
Identification of the transcription start
The sequence 1 kb upstream of the ATG start codon pos-
sesses neither TATA or CAAT boxes, but contains scattered
initiator (Inr) elements (consensus Py Py C A N T/A Py Py)
[16]. In order to determine the transcription start site
(tss), we therefore performed RNA ligase mediated rapid
amplification of cDNA ends [17]. By Northern blotting
Genomic organization of GP210 and a model of the deduced amino acid chain of GP210 Figure 1
Genomic organization of GP210 and a model of the deduced amino acid chain of GP210. Exons (black boxes) and 
intron sizes are scaled individually. In silico predictions of a signal peptide, the transmembrane region and 12 putative N- linked 
glycosylation sites (N).Journal of Negative Results in BioMedicine 2004, 3:7 http://www.jnrbm.com/content/3/1/7
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using a 935 bp cDNA probe (nt 4286–5220), a single
transcript of 7,3 kb was seen in two different tumor cell
lines (Fig 2). The size of the mRNA corresponds to the
sum of the open reading frame and 3'-UTR including a
potential poly A tail. Since expression was much more
abundant in HeLa cells than in Wilms tumor cells, we
used HeLa cell total RNA as a template. The nested PCR
(see material and methods) gave a major specific cDNA
product of approximately 80 nucleotides (fig. 3, lane 2).
Sequence analysis of 10 independently ligated PCR prod-
ucts obtained using nested adapter- and gene specific
primers (outlined in fig. 3) revealed two different ampli-
fied, GP210 specific fragments of similar length, indicat-
ing two alternative tss (Fig. 4). Out of ten clones
sequenced, eight ended at position -29 and two at posi-
tion -18 upstream ATG. In an identical analysis using
poly-A+ RNA from a human fetal myoblast cell line G6, 7
clones ended at position -29 and 3 at position -18
upstream ATG. These findings argue for a major tss at -29.
In addition, to confirm our findings we performed
sequence homology searches in the human EST clone
database at NCBI and elsewhere. The results revealed no
reported cDNA sequences located upstream of the experi-
mentally determined start site.
Promoter sequence analysis
Analysis of the sequence surrounding the translation start
site with the GRAIL program predicted a 1236 bp long
CpG island, with a GC content of 75.3% starting 434 bp
upstream of ATG, covering the first exon and extending
into the first intron. We used a variety of promoter and
transcription factor binding site algorithms to analyse the
region upstream the start site for GP210, including TESS
and Matinspector. By selecting for perfect matching and
human consensus motifs a restricted number of putative
transcription factor binding sites were found. Using these
criteria, 22 motifs recognized by 14 different factors were
defined on the sense strand, evenly distributed within
1000 bp proximal to the translation start codon (See
Table 2, additional file 2). Seven Sp1 binding motifs were
identified [18], five of them clustered in a region spanning
315 bases, starting eight nucleotides upstream of the
major tss (Fig. 4). Four putative binding motifs for EGR1/
WT1 (consensus GXGXGGGXG) were mapped within the
same promoter region, starting at positions -47, -70, -76
and -283. Two of these matched completely with this con-
sensus sequence, whereas two contained one mismatch in
the 9bp-binding motif (positions -71 and -284 respec-
tively). In addition, we found a WT1 binding site in the
antisense strand (pos. -112). Only a few other upstream
regulatory elements were defined within and proximate to
the CpG rich region. We found one binding motifs associ-
ated to Ets-2 [19], one to the c-myc purine-binding tran-
scription factor PuF [20] and one to the early growth
response gene 2 (table 2, Fig. 4).
A sequence of 9433 bp (c047302867. Contig1) was found
in the Mouse Genome Sequencing Consortium (MGSC)
database. This sequence mapped to mouse chromosome
6 and contained the first exon, part of the first intron, and
3 kb of the upstream promoter region of mouse GP210.
Similar to human, a GPC island containing 644 bp and
with a GC content of 74% was found starting 268 nt
upstream of the start codon and extending into the gene.
Pairwise ClustalW alignment of this genomic clone
showed 54% homology to its human counterpart within
the first 500 bp upstream of the translation start (fig. 4).
In the same region as in human we found putative EGR1/
WT1 binding sequences. The sequence at positions -40 to
-32 matched completely with the consensus sequence.
The sequences starting at -47, -76, and -283 had one, two
and one mismatches, respectively. As in the human
sequence, an additional putative WT1 binding site was
Northern blot analysis of HeLa cell and WCCS-1 mRNA Figure 2
Northern blot analysis of HeLa cell and WCCS-1 
mRNA. A 935 bp GP210 specific cDNA probe was hybrid-
ized to 10 µg of HeLa and WCCS-1. Loading and RNA qual-
ity was controlled by a methyleneblue staining of 18 and 28s 
rRNA.Journal of Negative Results in BioMedicine 2004, 3:7 http://www.jnrbm.com/content/3/1/7
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located in the antisense strand starting at position -83, but
it contained a single nucleotide insertion. An Ets-2 motif,
identical to the motif starting at -500 in the human
sequence, was found starting at position -390 in the
mouse sequence. In addition, a 40 bp (GT)n repetitive
sequence was located about 1700 bp upstream of the ATG
both in the human and mouse promoter (Fig. 5). This
repetitive sequence is known to exist redundantly in the
genome [21], and has been reported to be a binding ele-
ment for WT1 [22,23].
To determine whether the putative WT1 binding sites in
the GP210 promoter might correspond to functional reg-
ulation of GP210 by WT1, we used a model system for the
examination of WT1 target genes in which WT1- isoform
A, devoid of a 17 amino acid insert and a KTS insert in the
zinc finger region, was expressed upon removal of tetracy-
cline from the growth media. Figure 6 shows in a triplicate
experiment that the induction of WT1 (Lanes 4–6) in
these cells did not alter GP210 transcription. An actin con-
trol showed comparable loading and integrity of mRNA.
These data suggest that GP210 is not a target of WT1.
Discussion
The present study describes the genomic structure of the
human nucleoporin GP210 gene, including its exon and
Determination of 5 prime end of GP210 mRNA Figure 3
Determination of 5 prime end of GP210 mRNA. Transcription start site were determined analyzing nested PCR prod-
ucts generated with gene (fig. 5) and adapter specific primers. Lane 1, Marker. Lane 2, Nested PCR product obtained using two 
primer pairs specific to sequences within the adapter and the first exon. Lane 3, Negative water control. Lane 4, Positive con-
trol using bacterial adapter ligated cDNA and specific primers. Lane 5, Marker.Journal of Negative Results in BioMedicine 2004, 3:7 http://www.jnrbm.com/content/3/1/7
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Promoter analysis human GP210 and homology to its mouse counterpart Figure 4
Promoter analysis human GP210 and homology to its mouse counterpart. A 500 bp sequence upstream of transla-
tion start site was analyzed for the presence of consensus transcription factor binding sites. Upper lane is the human sequence, 
and lower sequence is mouse. Homology in the (GT)n repeat between human and mouse genomic sequences and its position 
relative to the translation start codon. The translation start site is in bold and numbered +1. Homology to the mouse sequence 
is marked in grey, Outer gene specific primer (ogsp) and inner gene specific primer (igsp) used for transcription start definition 
using RLM-RACE are underlined with arrows. The transcription initiation sites are positioned with empty arrows and the start 
nucleotide is in bold. Putative transcription binding motifs are underlined. Some elements for different transcription factors 
overlap. Only sense strand binding sites were considered. Legend: Sp1, Simian-virus-40-protein 1; EGR2, Early growth 
response gene 2; WT1, Wilms' tumor zink finger protein 1; PuF, c-myc purine-binding transcription factor.Journal of Negative Results in BioMedicine 2004, 3:7 http://www.jnrbm.com/content/3/1/7
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intron sizes, intron/exon junctions and the 5' UTR
sequence. Transcription start sites were determined exper-
imentally by RNA ligase mediated rapid amplification of
cDNA ends. Analysis of the promoter sequence identified
a number of putative binding motifs for factors involved
in tissue- or cell -type specific gene regulation. Strikingly,
we could identify five putative Wilms tumor 1 (WT1) sup-
pressor protein binding sites, four Sp1 biding sites, and
one ETS binding site in a range of 315 bases just upstream
of the translation initiation site. Some of these were con-
served in the mouse promoter region.
Mouse GP210 was initially identified as an early response
gene to induction of embryonic kidney tubule develop-
ment [10,15], suggesting that transcription factors regulat-
ing conversion of mesenchyme to kidney tubules are
involved in its activation. Transcription factors implicated
in early kidney tubule development include members of
the myc family, Pax-2, hox a11 and Hoxd11, lmx-1b,
HNF-1a, Pod-1, and WT1 [24-29]. Except for the WT1
binding site, putative binding motifs for these factors were
lacking in the promoter region of the GP210 gene. Exper-
imentally we found that WT1 does not influence GP210
expression in human osteosarcoma cells. It is thus more
likely that Sp1 and some member of the ETS transcription
factor family are the positive regulators of GP210.
WT1 is a zinc finger transcription factor known to exist in
different isoforms due to alternative pre-mRNA splicing.
DNA binding specificity is determined by insertion or
removal of three amino acids between zinc finger III and
IV (referred to as WT1(+KTS) and WT1(-KTS)). The -KTS
isoform have been reported to repress or activate target
genes containing variations of an EGR1 related, GC-rich
motif (consensus GXGXGGGXG) in their promoter [24].
Other biological activities have been suggested for the
+KTS isoform [26]. Mutations in the WT1 gene has been
shown in a small proportion of nephroblastomas, an
embryonic kidney tumor, as well as in other tumor types,
such as leukemia, mesothelioma and desmoplastic small
round cell tumor. The restricted expression pattern in the
mouse embryonic kidney and the failure of kidney devel-
opment in WT1 null mice shows that WT1 is important
for mesenchyme-to-epithelial transition, especially for
early organogenesis of kidney and gonads [29]. It is thus
of considerable importance to identify downstream target
genes for WT1. This could include the gene for GP210, but
presumably not other nucleoporins. In the only previ-
ously reported nucleoporin promoter region, of mouse
nup358, several binding sites for Sp1 but none for WT1
were detected [25,30].
Sp1 is a transcription factor included in a small protein
family (Sp1, Sp2, Sp3, and Sp4), whose members are
binding to cis-elements widely distributed in different
types of transcription control regions [25]. Although tra-
ditionally considered as an activator for house keeping
genes, it has become increasingly clear that Sp1 can act as
a cell specific regulator of gene expression. Differential
expression levels of Sp1 during nephrogenesis [31] and
hematopoietic development [32] have been reported.
Along with specific post-translational modifications, the
substantial differences in the expression patterns of Sp1
suggest that Sp1 can induce specific gene expression in
embryonic tissues, including GP210 in the kidney.
We also found a putative ETS-2 binding site in the mouse
and human promoter for gp/GP210. Ets-2 is a widely
Alignment of mouse and human sequences demonstrating a conserved region about 1700 bp upstream of ATG Figure 5
Alignment of mouse and human sequences demonstrating a conserved region about 1700 bp upstream of ATG.Journal of Negative Results in BioMedicine 2004, 3:7 http://www.jnrbm.com/content/3/1/7
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distributed member of the ETS family of transcription fac-
tors characterized by a unique winged helix-turn-helix
domain, which specifically interacts with DNA sequences
containing the purine-rich core motif, GGAA/T. Since sev-
eral ETS family members binds to the same core motif it
has been difficult to determine specific target genes for
each member, gene targeting in mice implicates ETS-2 as
an activator of metalloproteinases in placenta (MMP-3,
MMP-9 and MMP-13) and a regulator of hair develop-
ment [33]. Elevated ETS-2 expression can reverse ras
dependent transformation in cell lines [34]. In contrast, a
high expression of ETS-2 is needed to maintain the trans-
formed state of human prostate cells [35]. These data sug-
gests multiple roles for ETS-2 during development and
cancer. Interestingly, a binding site for Pea3, a member of
the ETS family, has been noted in the WT1 promoter, and
Pea3 was found to transactivate the Wt1 promoter [36].
Our promoter region analyses, which identify WT1, SP1
and Ets-2 as putative transcription factors regulating
GP210 expression are descriptive. GP210 expression in
the developing kidney resembles that of E-cadherin,
which has been show to be a bone fide WT1 target gene
[24]. WT1 A isoform, which lacks a 17 amino acid insert
and the KTS insert in the zinc finger region, did not influ-
ence GP210 expression in SAOS osterosarcoma cells, in a
system using tetracycline-induced repression of expres-
sion. In vivo, expression of WT1 appears very early during
nephrogenesis, and is downregulated when GP210
expression increases [10,15,28,29]. Based on these
findings, it was difficult to predict whether WT1 is
involved in the positive or negative regulation of GP210.
Our data do not exclude the possibility that demonstrate
that the WT1 A isoform in different setting can regulate
GP210 expression. It is also possible that other isoforms
of WT1 regulate GP210.
The amino acid sequence of human GP210 revealed
potential sites for phosphorylation and glycosylation. The
role for phosphorylation of nuclear envelope associated
proteins is not well understood, but is presumed to have
a function in mitotic events [37,38]. Non-membrane
nucleoporins 153, 214 and 358 are phosphorylated
throughout the cell cycle, but hyperphosphorylated dur-
ing cell division. In contrast, GP210, was in the same
study specifically phosphorylated during mitosis and one
single consensus Ser1880-Pro1881 motif could be detected
as a target for cyklin-B-p34cdc2 kinase and MAP kinase in
vitro [39]. A comparison of the cytoplasmic domain in
mouse, rat and human reveals that this serine-proline
dipeptide located seven amino acids downstream of the
carboxyl terminus is conserved. Whether the many puta-
tive phosphorylation sites in GP210 are actively regulated
has to be experimentally determined. Restricted to the
lumenal region of GP210, there are 12 potential putative
acceptor residues for N-linked oligosaccharides. This is
one residue less than in the rat homologue [5], but the
remaining 11 seem to be located at conserved locations.
The binding of GP210 to the lectin ConA suggests pres-
ence of high mannose-type oligosaccharides in mature
GP210 [4], but there are no reports on functional aspects
of this posttranslational modification.
WT1 isoform A does not regulate expression of GP210 Figure 6
WT1 isoform A does not regulate expression of 
GP210. SAOS cells conditionally expressing WT1 isoform A 
were grown in the presence (Lanes 1–3) or absence (lane 4–
6) of tetracycline to induce expression of WT1. Triplicate 
plates of cells were harvested for total RNA and subjected to 
sequential northern blot analysis with the GP210 probe, 
WT1probe and actin control.Journal of Negative Results in BioMedicine 2004, 3:7 http://www.jnrbm.com/content/3/1/7
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Materials and methods
Wilms tumor and HeLa cell cultures
WCCS-1 Wilms tumor cells [40] and HeLa cells were cul-
tured in Dulbecco's modified medium containing 10%
heat- inactivated Fetal Calf Serum (FCS) and in the pres-
ence of 1% HEPES. RNA from WCCS-1 and HeLa cells was
isolated from 5 × 107 cells using the RNAeasy midi kit
(Qiagen) following the recommendations of the manu-
facturer, including a DNAse treatment step to avoid chro-
mosomal DNA contaminations. Northern blotting of
total RNA from cells was performed as described [41]. To
visualize 18 and 28s rRNA, a control RNA filter lane were
immersed in 5% acetic acid followed by colorization in
0,5 MNaAc (pH 5,2), 0,4% methyleneblue for 15 min.
cDNA probes used: a 935 bp PCR generated GP210 probe
(nt 4286–5220), a 1.8 kb human β-Actin control probe
(Clontech) and a 1023 bp PCR generated human WT1
probe covering the 3' end of the ORF and 523 bp of the 3'
untranslated region thereby hybridizing to all known
splice variants [42]. Probes were labelled with [α32P]
dCTP by random priming using Megaprime DNA labeling
system kit (Pharmacia). Filters were hybridized in 20 mM
Na2HPO4 (pH 7.2), 7% SDS at 65°C for 18 hours. After
washing in 20 mM Na2HPO4 (pH 7.2), 5% SDS at 65°C
for 2 × 60 min followed by 2 × 60 min in 20 mM
Na2HPO4 (pH 7.2), 1% SDS at 65°C the filters were
exposed to Hyperfilm-MP films (Amersham) for 5 days at
-70°C in the presence of intensifying screens. Band
intensities were quantified using a PhosphoImager 400S
(Molecular Dynamics, Sunnyvale, CA).
Tetracycline-regulated expression of WT1 in human 
osteosarcoma cells
WT1-A SAOS cells were constructed from a cell line har-
boring the tetracycline-repressor-VP16 fusion protein
[43], transfecting the parental cell with a construct
harboring WT1 isoform A (-17amino acids, -KTS) linked
3' to the CMV minimal promoter and tetracycline opera-
tors [44]. Conditional expression of WT1-A was demon-
strated by immunoblotting. WT1-A-SAOS cells were
maintained in Dulbecco's modified Eagle's medium sup-
plemented with 10% fetal calf serum, 1∞ penicillin/strep-
tomycin, 0.3 mg/mL L-glutamine and 0.5 mg/mL G418.
All cells were cultured at 37°C in a 5% CO2 atmosphere.
For the induction, cells (at 70% confluence) were washed
twice with PBS and refed with fresh media in the absence
or presence of 1 µg/mL of Tetracycline. After 18 hours, the
cells were washed twice with PBS and total RNA was iso-
lated using TRIzol reagent (Invitrogen, Carlsbad, CA)
according to the manufacture's instructions. 4 µg of the
RNA were resolved on formaldehyde-containing agarose
gels and transferred to Nytran membranes (Schleicher and
Schuell, Keene, NH). Hybridization was performed in
ULTRAhyb buffer (Ambion, Austin, TX) at 42°C. Briefly,
filters were prehybridized in ULTRAhyb buffer for 6 hours
followed by an overnight hybridization at 42°C with the
935 bp hGP210cDNA probe. A WT1 cDNA probe (exons
5 to 10) and a cDNA probe for actin were used as controls.
Membranes were exposed to BIOMAX MS films (Kodak,
Rochester, NY) at -80°C in the presence of intensifying
screens. Probes were stripped by boiling the membranes
in 0.1% sodium dodecyl sulfate/ standard saline citrate
solution for 10 minutes.
Oligo-capping
To determine transcription start, the RNA Ligase Mediated
Rapid Amplification of cDNA Ends (RML-RACE) kit
(Ambion) was used according to the instructions of the
manufacturer's. Briefly 5 µg of Hela cell RNA or 2–5 µg of
poly-A+ RNA from partially differentiated human G6 sat-
ellite cells [45] was treated with calf intestinal phos-
phatase (CIP) at 37°C for 60 min. RNA from G6 cells was
kindly provided by Donald Gullberg at ICM, Uppsala
University, Sweden. The mixture was phenol:chloroform
(1:1) extracted followed by ethanol precipitation. The
RNA was subsequently incubated with Tobacco Acid
Phosphatase (TAP) at 37°C for 60 min. A 45 nt adapter
RNA oligonucleotides
(5'GCUGAUGGCGAUGAAUGAACACUGCGUUUGCUG
GCUUUGAUGAAA3') was ligated to the CIP/TAP treated
5' RNA end using T4 ligase. cDNA was generated using
random decamers and MMLV reverse transcriptase at
42°C for one hour. The nested PCR were performed using
the advantaq 2 polymerase system (Clontech) and the fol-
lowing primers: in the first PCR reaction the outer adapter
(5'GCTGATGGCGATGAATGAACACTG3') was combined
with the gene specific outer primer
(5'CAGCAGCACTTTGGGGATGTTGAG3'), in the second
PCR the inner adapter primer (5'CGCGGATC-
CGAACACTGCGTTTGCTGGCTTTGATG-3') was used in
combination with the gene specific inner primer
(5'CCCGCCGCCAACAGCACCGACAGC3'). The condi-
tions for both PCR reactions were as follows: 94°C for one
min (hot start) followed by 95°C for 20 s, 68°C for 60 s,
repeated 35 cycles. After the final cycle, the reactions were
extended for an additional 5 min at 68°C. PCR products
were analysed on a 2% agarose gel, ligated into the pCRII
vector (Invitrogen) and sequenced using M13 primers.
Sequencing
Sequencing was performed using ABI PRISM and the Dye
Terminator cycle sequencing kit according to the manu-
facturer's directions (Perkin Elmer) and analysed by an
automated ABI-310 fluorescent-dy sequencer (Applied
Biosystems).
Bioinformatics and sequence analyses
Exon-intron boundary predictions were done manually
and using the Genscan web server at MIT http://
genes.mit.edu/GENSCAN.html. Open reading frameJournal of Negative Results in BioMedicine 2004, 3:7 http://www.jnrbm.com/content/3/1/7
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finding and all sequence analyses were done using the
MacVector 6.5.3 sequence analysing software (Oxford
Molecular Group). The BLAST (Basic Local Alignment
Search Tool) server of the National Center of Biotechnol-
ogy Information (NCBI) http://www.ncbi.nlm.nih.gov/
BLAST/ and The Mouse Genome Sequencing Consortium
(MGSC) database http://www.ensembl.org/
Mus_musculus/ was used for sequence alignments. Signal
peptide prediction was done using the SignalP v1.1 at
WWW Prediction Server (Center for Biological Sequence
Analysis, and membrane topology predictions at the
HMMTOP server using the TopPred2 program [46]. Tran-
scription factor mapping in the 5' untranslated region of
hGP210 was analysed in TESS http://
www.cbil.upenn.edu/tess and Matinspector [47] search
programs. Additional amino acid sequence patterns and
domains were analysed using the PROSITE database http:/
/www.expasy.ch/prosite/. Prediction of GPC islands and
detection of repeats in sequences analysed were done with
the GRAIL program [48].
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